Business Context and Reporting Period
This summary covers the Form 10-Q filed by Schering-Plough Corporation for the quarterly period ended September 30, 2000. The company operates in the pharmaceutical, animal health, and consumer health sectors. The filing includes unaudited consolidated financial statements for the three and nine months ended September 30, 2000, compared to the same periods in 1999.
Key Financial Metrics
| Metric (in millions) | 3 Months Ended Sep 30, 2000 | 3 Months Ended Sep 30, 1999 | 9 Months Ended Sep 30, 2000 | 9 Months Ended Sep 30, 1999 |
|---|---|---|---|---|
| Net Sales | $2,394 | $2,236 | $7,442 | $6,873 |
| Net Income | $591 | $518 | $1,852 | $1,604 |
| Diluted EPS | $0.40 | $0.35 | $1.25 | $1.08 |
| Operating Cash Flow (9mo) | $1,999 | $1,416 | ||
| Cash and Equivalents (Sep 30) | $2,181 | $1,876 (Dec 31, 1999) | ||
| Short-term Borrowings | $715 | $728 (Dec 31, 1999) | ||
| Long-term Liabilities | $968 | $1,001 (Dec 31, 1999) |
Margins (9 Months 2000 vs 1999):
- Cost of Sales: 19.0% (down from 19.5%)
- Selling, General & Administrative: 36.1% (down from 37.4%)
- Research & Development: 13.1% (up from 12.6%)
- Effective Tax Rate: 24.0% (down from 24.5%)
Material Changes vs. Prior Period
- Sales Growth: Net sales increased 7% in the quarter and 8% year-to-date. Excluding foreign currency impacts, growth was 9% and 10% respectively. International sales grew 19% excluding exchange rates.
- Profitability: Net income rose 14% in the quarter and 16% year-to-date. Income before taxes increased 13% (quarter) and 15% (year-to-date).
- Product Performance:
- Allergy & Respiratory: Sales up 6% (quarter) and 8% (YTD), driven by CLARITIN (+10% quarter) and NASONEX (+29% franchise growth).
- Anti-infective & Anticancer: Sales up 23% (quarter) and 21% (YTD), led by INTRON A/REBETRON and new launches of TEMODAR and REMICADE.
- Declines: VANCERIL and PROVENTIL sales declined due to manufacturing issues and generic competition. OTC sales dropped 8% YTD following the sale of the PAAS product line.
- Acquisitions: Acquired a majority interest in a joint venture with Takeda Chemical Industries for animal health products in Japan for approximately $48 million.
- Shareholder Returns: Repurchased $644 million of common shares YTD (19% of the $1.5 billion authorization). Increased quarterly dividend to $0.14 per share.
Guidance, Outlook, and Risks
Guidance: Management reiterated a full-year 2000 diluted earnings per share projection of approximately $1.64, representing a 15% increase over 1999. The company expects Q3 and Q4 earnings growth rates to be comparable to the full-year increase.
Management Commentary:
- Foreign currency weakness continues to negatively impact reported sales comparisons.
- Capital expenditures are expected to exceed $750 million in 2000, including a new research facility in Summit, NJ.
- Operating cash flow increased significantly due to higher net income and reduced working capital investment.
Risks and Contingencies:
- Patent Litigation: Multiple challenges to CLARITIN patents by generic manufacturers (Geneva, Copley, Teva, etc.) and a suit by Hoffmann-La Roche regarding PEG-INTRON. Outcomes are uncertain but could materially affect sales.
- Regulatory Investigations: Ongoing investigations by the FTC (antitrust/price-fixing), DOJ, and HHS regarding marketing practices, disease management programs, and average wholesale prices (AWP). Potential fines or penalties cannot be predicted.
- Legal Proceedings:
- Antitrust class actions (federal settled for $22 million; state actions largely settled or dismissed).
- Texas lawsuit against subsidiary Warrick Pharmaceuticals alleging false wholesale price reporting (claim approx. $54 million).
- Environmental cleanup liabilities (Superfund sites) and a class action in Puerto Rico regarding wastewater odors (claim $600 million).
- Manufacturing Issues: FDA Warning Letters regarding aerosol product facilities (albuterol/VANCERIL) led to voluntary recalls and remedial actions.
Investor Verification Checklist
- Patent Expirations: Verify the status of CLARITIN patent litigation and potential timelines for generic entry.
- Regulatory Outcomes: Monitor the status of FTC and DOJ investigations into pricing and marketing practices for potential fines.
- Manufacturing Compliance: Confirm resolution of FDA concerns regarding New Jersey aerosol facilities to ensure no future supply disruptions.
- Foreign Exchange Impact: Assess the sensitivity of future earnings to continued weakness in European currencies.
- Capital Allocation: Track progress of the $1.5 billion share repurchase program and capital expenditure plans.